Pamiparib and Low Dose Temozolomide In Patients With Platinum Sensitive Biliary Tract Cancer
Latest Information Update: 03 Jun 2022
At a glance
- Drugs Pamiparib (Primary) ; Temozolomide (Primary) ; Cisplatin; Gemcitabine; Oxaliplatin
- Indications Adenocarcinoma; Biliary cancer; Cholangiocarcinoma; Gallbladder cancer; Periampullary cancer
- Focus Therapeutic Use
- Acronyms PAMICC
- 27 May 2022 Planned initiation date changed from 1 Sep 2021 to 1 May 2022.
- 27 May 2022 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 16 Mar 2021 New trial record